Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.53 |
| ▸ | RIPK1 | Q13546 | 13/20 | 0.50 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.46 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.45 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SNCA | P37840 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinoline SCHEMBL28069084 | 0.89 | ALDH1A1 (0.57) | DAORIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL15528142 | 0.77 | DAO (0.65) | DAORIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL8134947 | 0.76 | DAO (0.46) | DAORIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL745278 | 0.75 | DAO (0.53) | DAORIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL27984199 | 0.75 | DAO (0.53) | DAORIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL575029 | 0.75 | DAO (0.53) | DAORIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL27680363 | 0.75 | DAO (0.62) | DAORIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL30678374 | 0.75 | DAO (0.62) | DAORIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL1176828 | 0.75 | DAO (0.53) | DAORIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL7639694 | 0.75 | RIPK1 (0.59) | DAORIPK1CCNB2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112159423-A | Synthesis method of 1H-pyrrolo [2,3-b ] pyridine-2-boronic acid pinacol ester | 凯美克(上海)医药科技有限公司 | 2021-01-01 | — | — | CN | claimed |
| CN-110498798-A | A kind of microreactor series connection synthetic method of indoles anti-tumor drug molecule | UNIV FUDAN | 2019-11-26 | — | — | CN | claimed |
| CN-107043395-A | A kind of synthetic method of azaindole substituted boracic acid class compound | 江苏常州酞青新材料科技有限公司 | 2017-08-15 | — | — | CN | claimed |
| CN-105622605-A | Synthesis method of 5-bromo-7-azaindole | ITIC MEDCHEM CO LTD | 2016-06-01 | — | — | CN | claimed |
| US-20250326772-A1 | MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER | KYORIN SEIYAKU KK (JP) | 2025-10-23 | — | — | US | disclosed |
| US-20250326773-A1 | MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER | KYORIN SEIYAKU KK (JP) | 2025-10-23 | — | — | US | disclosed |
| CN-119954831-A | Pyrimidopyrazoles, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-118344359-A | RIPK1 kinase targeted inhibitor and application thereof | 中国药科大学 | 2024-07-16 | — | — | CN | disclosed |
| WO-2024097355-A1 | DEUBIQUITINASE-TARGETING CHIMERAS AND RELATED METHODS | VICINITAS THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024097355-A1 | DEUBIQUITINASE-TARGETING CHIMERAS AND RELATED METHODS | VICINITAS THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| CN-117126157-A | Preparation method of 5-hydroxy-7-azaindole | 舞阳威森生物医药有限公司 | 2023-11-28 | — | — | CN | disclosed |
| CN-112159423-A | Synthesis method of 1H-pyrrolo [2,3-b ] pyridine-2-boronic acid pinacol ester | 凯美克(上海)医药科技有限公司 | 2021-01-01 | — | — | CN | disclosed |
| US-5998432-A | SEXUAL DISORDERS | MERCK & CO., INC. (US) | 1999-12-07 | — | — | US | disclosed |
| US-5985892-A | USEFUL FOR THE TREATMENT OF A VARIETY OF SEX-HORMONE RELATED AND OTHER CONDITIONS IN BOTH MEN AND WOMEN; PREVENTING PREGNANCY; TREATING LUPUS ERYTHEMATOSIS, IRRITABLE BOWEL SYNDROME, PREMENSTRUAL SYNDROME, HIRSUTISM, SHORT STATURE OR A | MERCK & CO., LTD. (US) | 1999-11-16 | — | — | US | disclosed |
| WO-1999051232-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1999-10-14 | — | — | WO | disclosed |
| WO-1999051234-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1999-10-14 | — | — | WO | disclosed |
| WO-1999051233-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1999-10-14 | — | — | WO | disclosed |
| WO-1999051596-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1999-10-14 | — | — | WO | disclosed |
| WO-1999051231-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1999-10-14 | — | — | WO | disclosed |
| WO-1999051595-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1999-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326772-A1 | MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER | MRGPRX2, MRGPRX1, MRGPRX4 | DAO 2921/4885RIPK1 3652/4885CCNB2 4212/4885 |
| US-20250326773-A1 | MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER | MRGPRX2, MRGPRX1, MRGPRX4 | DAO 2921/4885RIPK1 3652/4885CCNB2 4212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.